TEM-187，一种新的超广谱β-内酰胺酶，在奇异变形杆菌临床株中活性较弱。
TEM-187, a new extended-spectrum β-lactamase with weak activity in a Proteus mirabilis clinical strain.
机构信息
Service de Bactériologie-Hygiène, CHU de Nantes, Institut de Biologie, Nantes, France.
出版信息
Antimicrob Agents Chemother. 2013 May;57(5):2410-2. doi: 10.1128/AAC.01761-12. Epub 2013 Mar 11.
Abstract
A Proteus mirabilis clinical strain (7001324) was isolated from urine sample of a patient hospitalized in a long-term-care facility. PCR and cloning experiments performed with this strain identified a novel TEM-type β-lactamase (TEM-187) differing by four amino acid substitutions (Leu21Phe, Arg164His, Ala184Val, and Thr265Met) from TEM-1. This characterization provides further evidence for the diversity of extended-spectrum β-lactamases (ESBL) produced by P. mirabilis and for their potential spread to other Enterobacteriaceae due to a lack of sensitive detection methods used in daily practice.
摘要
一株奇异变形杆菌临床分离株（7001324）从长期护理机构住院患者的尿液样本中分离得到。对该分离株进行的 PCR 和克隆实验鉴定出一种新型 TEM 型β-内酰胺酶（TEM-187），与 TEM-1 相比，该酶有 4 个氨基酸取代（Leu21Phe、Arg164His、Ala184Val 和 Thr265Met）。这一特征进一步证明了奇异变形杆菌产生的超广谱β-内酰胺酶（ESBL）的多样性，以及由于日常实践中缺乏敏感的检测方法，它们有可能传播到其他肠杆菌科。
相似文献
1
TEM-187, a new extended-spectrum β-lactamase with weak activity in a Proteus mirabilis clinical strain.
Antimicrob Agents Chemother. 2013 May;57(5):2410-2. doi: 10.1128/AAC.01761-12. Epub 2013 Mar 11.
2
Emerging extended-spectrum beta-lactamases in Proteus mirabilis.
J Clin Microbiol. 2002 Apr;40(4):1549-52. doi: 10.1128/JCM.40.4.1549-1552.2002.
3
Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria.
J Glob Antimicrob Resist. 2019 Sep;18:249-256. doi: 10.1016/j.jgar.2019.01.030. Epub 2019 Feb 21.
4
TEM-72, a new extended-spectrum beta-lactamase detected in Proteus mirabilis and Morganella morganii in Italy.
Antimicrob Agents Chemother. 2000 Sep;44(9):2537-9. doi: 10.1128/AAC.44.9.2537-2539.2000.
5
The new variant of Salmonella genomic island 1 (SGI1-V) from a Proteus mirabilis French clinical isolate harbours blaVEB-6 and qnrA1 in the multiple antibiotic resistance region.
J Antimicrob Chemother. 2011 Nov;66(11):2513-20. doi: 10.1093/jac/dkr335. Epub 2011 Aug 16.
6
TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3.
Antimicrob Agents Chemother. 2001 Dec;45(12):3591-4. doi: 10.1128/AAC.45.12.3591-3594.2001.
7
Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Int J Antimicrob Agents. 2001 Feb;17(2):131-5. doi: 10.1016/s0924-8579(00)00325-3.
8
Characterization of the Genetic Environment of the bla Gene, Associated with a Transposable Region in a Proteus mirabilis Clinical Isolate.
Microb Drug Resist. 2017 Oct;23(7):833-837. doi: 10.1089/mdr.2016.0262. Epub 2017 Mar 17.
9
New TEM variant (TEM-92) produced by Proteus mirabilis and Providencia stuartii isolates.
Antimicrob Agents Chemother. 2001 Apr;45(4):1278-80. doi: 10.1128/AAC.45.4.1278-1280.2001.
10
New variant of TEM-10 beta-lactamase gene produced by a clinical isolate of proteus mirabilis.
Antimicrob Agents Chemother. 1995 May;39(5):1199-200. doi: 10.1128/AAC.39.5.1199.
引用本文的文献
1
Characterization and risk assessment of novel SXT/R391 integrative and conjugative elements with multidrug resistance in isolated from China, 2018-2020.
Microbiol Spectr. 2024 Feb 6;12(2):e0120923. doi: 10.1128/spectrum.01209-23. Epub 2024 Jan 10.
2
Evolving Bacterial Fitness with an Expanded Genetic Code.
Sci Rep. 2018 Feb 19;8(1):3288. doi: 10.1038/s41598-018-21549-w.
本文引用的文献
1
Outbreak caused by Proteus mirabilis isolates producing weakly expressed TEM-derived extended-spectrum β-lactamase in spinal cord injury patients with recurrent bacteriuria.
Scand J Infect Dis. 2011 Dec;43(11-12):957-61. doi: 10.3109/00365548.2011.601756. Epub 2011 Sep 5.
2
Incidence of class A extended-spectrum beta-lactamases in Champagne-Ardenne (France): a 1 year prospective study.
J Antimicrob Chemother. 2007 Nov;60(5):956-64. doi: 10.1093/jac/dkm319. Epub 2007 Sep 5.
3
Increased resistance to beta-lactams in a Klebsiella pneumoniae strain: role of a deletion downstream of the Pribnow box in the blaSHV-1 promoter.
Int J Antimicrob Agents. 2006 Oct;28(4):308-12. doi: 10.1016/j.ijantimicag.2006.07.004. Epub 2006 Sep 7.
4
CMT-type beta-lactamase TEM-125, an emerging problem for extended-spectrum beta-lactamase detection.
Antimicrob Agents Chemother. 2006 Jul;50(7):2403-8. doi: 10.1128/AAC.01639-05.
5
Extended-spectrum beta-lactamase genes of Klebsiella pneumoniae strains in Taiwan: recharacterization of shv-27, shv-41, and tem-116.
Microb Drug Resist. 2006 Spring;12(1):12-5. doi: 10.1089/mdr.2006.12.12.
6
TEM-109 (CMT-5), a natural complex mutant of TEM-1 beta-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5).
Antimicrob Agents Chemother. 2005 Nov;49(11):4443-7. doi: 10.1128/AAC.49.11.4443-4447.2005.
7
8
TEM-121, a novel complex mutant of TEM-type beta-lactamase from Enterobacter aerogenes.
Antimicrob Agents Chemother. 2004 Dec;48(12):4528-31. doi: 10.1128/AAC.48.12.4528-4531.2004.
9
AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains.
J Antimicrob Chemother. 2003 Oct;52(4):629-35. doi: 10.1093/jac/dkg407. Epub 2003 Sep 1.
10
Promoters P3, Pa/Pb, P4, and P5 upstream from bla(TEM) genes and their relationship to beta-lactam resistance.
Antimicrob Agents Chemother. 2002 Dec;46(12):4035-7. doi: 10.1128/AAC.46.12.4035-4037.2002.
Zotero 插件